IL6 and lung cancer: Treatment with Canakinumab, a monoclonal antibody against IL-1β, led to a dose-dependent reduction in the concentrations of the inflammation markers high-sensitivity C-reactive protein and interleukin 6 (IL-6) as well as a reduction in lung cancer incidence and mortality.